Human interleukin-2
- Generic Name
- Human interleukin-2
- Drug Type
- Biotech
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
Phase 2
Not yet recruiting
- Conditions
- SLE (Systemic Lupus)CMV
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06971913
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Bejing, China
Phase I/II Clinical Trial f CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1
Not yet recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 36
- Registration Number
- NCT06961357
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
Phase 2
Not yet recruiting
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Target Recruit Count
- 130
- Registration Number
- NCT06884670
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Phase 1
Suspended
- Conditions
- Multiple SclerosisPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)Non-Active Secondary Progressive Multiple SclerosisNon-Active SPMSAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesDemyelinating DiseasesImmune System Diseases
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 34
- Registration Number
- NCT06677710
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Phase 1
Recruiting
- Conditions
- Brain TumorBrain MetastasesBrain CancerGliomaGliomas, MalignantGlioblastomaMeningioma
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06640582
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
Phase 2
Recruiting
- Conditions
- MelanomaNon Small Cell Lung CancerCervical Cancer
- Interventions
- Biological: NMA-LD regimenBiological: Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 40
- Registration Number
- NCT06630611
- Locations
- 🇪🇸
Vall d'Hebron Institute of Oncology, Barcelona, Spain
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Select Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 141
- Registration Number
- NCT06598371
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
Phase 2
Recruiting
- Conditions
- Hematological MalignancyLymphocytopenia
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Target Recruit Count
- 50
- Registration Number
- NCT06584006
- Locations
- 🇨🇳
Zhijuan Lin, Xiamen, Fujian, China
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
Phase 1
Recruiting
- Conditions
- Lung Cancer, Non-small CellLung Cancer RecurrentLung CancerLung Cancer Metastatic
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06538012
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Phase 1
Recruiting
- Conditions
- Stomach CancerStomach Cancer RecurrentStomach Cancer, AdenocarcinomaEsophageal CancerEsophageal Cancer Metastatic to BoneEsophageal Cancer Metastatic to LungEsophageal Cancer Metastatic to Liver
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 75
- Registration Number
- NCT06532799
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath